Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency

  title={Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency},
  author={Elleard Heffern and Rashmi Ramani and Garland R. Marshall and George B. Kyei},
  journal={Journal of Virus Eradication},
  pages={84 - 91}
Abstract Objectives Current antiretroviral therapy can suppress HIV replication, increase CD4 count and result in increased lifespan. However, it cannot eradicate the virus due to the presence of latent provirus in cellular reservoirs, such as resting CD4+ T cells. Using combination latency-reversing agents to shock the virus out of latency for elimination through immune clearance or viral cytopathic effect is one of the most promising strategies for HIV eradication. Specifically, recent… 
6 Citations

Figures and Topics from this paper

HIV latency reversal agents: A potential path for functional cure?
This review article focuses on the promising LRAs that have been described in the literature over the past few years, highlighting the advantages and disadvantages of their use in the 'kick and kill' approach, thus opening a new avenue in the development of a potential cure.
The Role of Macrophages in HIV-1 Persistence and Pathogenesis
Current antiretroviral therapy (ART) effectively suppresses Human Immunodeficiency Virus type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV-1 infected cells
Diverse synthesis of the C ring fragment of bryostatins via Zn/Cu-promoted conjugate addition of α-hydroxy iodide with enone
Abstract A convergent approach to 1,5-hydroxy ketones, the general precursors for constructing the C ring of bryostatins, has been developed via a Zn/Cu-promoted conjugate addition of α-hydroxy
Mini-review: Elucidating the psychological, physical, and sex-based interactions between HIV infection and stress
The relationship between stress and HIV, how these interact with sex, and to understand the physical ramifications of these interactions are elucidated.


Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
Comparative performance of lead bryologs are reported, including their effects in reducing cell surface expression of HIV entry receptors, inducing proinflammatory cytokines, inhibiting short-term HIV replication, and synergizing with histone deacetylase inhibitors to reverse HIV latency.
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
It is demonstrated that largazole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs and synergize with PKC modulators, namely bryostatin-1 analogues (bryologs), which induces HIV-1 reactivation to unparalleled levels and avoids global T-cell activation within resting CD4+ T-cells.
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
It is demonstrated that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.
Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
It is demonstrated that current in vitro models do not fully recapitulate mechanisms governing HIV-1 latency in vivo, and the data indicate that non-activating LRAs are unlikely to drive the elimination of the latent reservoir in vivo when administered individually.
Emerging strategies to deplete the HIV reservoir
HIV latency is multifactorial and thus the eradication of HIV infection may require multiple approaches, and translational efforts employing pharmacological methods to target HIV latency should evaluate in parallel the additional potential benefits of invigorating the immune response of HIV-infected individuals, and limiting the size of the reservoir via early ART.
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
A proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART demonstrates that significant reversal of HIV- 1 latency in vivo is possible without blunting T cell-mediated immune responses.
Targeting HIV latency: pharmacologic strategies toward eradication.
Current pharmacological approaches toward eradication of HIV-1 eradication are discussed, focusing on small molecule latency-reversing agents, their mechanisms, advantages and limitations.
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
These findings outline parameters for the experimental use of VOR to clear latent infection and suggest improvements in latency reversal may include the sustained induction of potent antiviral immune responses capable of recognizing and clearing the rare cells in which HIV latency has been reversed.
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication
The ability of HIV to establish a long-lived latent infection within resting CD4+ T cells leads to persistence and episodic resupply of the virus in patients treated with antiretroviral therapy
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
A reduction in the recovery of replication-competent virus from VOR exposed resting CD4 T cells following addition of immune effectors for a discrete period is shown.